As Director of the Wilmot Cancer Institute, I seek to provide the highest level of compassionate care for patients, ensuring access to novel treatments and clinical trials whenever possible. My background brings the entire continuum of lymphoma experience to patients, from diagnosis through all treatments including autologous stem cell transplantation, CAR-T cell interventions, novel agents, and survivorship.
We have built an incredibly strong team in Rochester to care for patients with lymphoma that is absolutely first rate and internationally recognized. We have expertise in hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. Driving this team toward excellence – and seeing our success – is highly rewarding.
Lymphoma is a complex set of diseases that can affect any organ system and I was drawn to that challenge. Our understanding of blood cancers in general, and specifically lymphoma, has enabled us to cure a subset of patients – and that also attracted me to this specialty. Happily, this fraction of cured patients has substantially increased during my 20-plus years in this field. Since lymphoma can affect anyone – males, females, young patients, older patients, and all ethnicities – I am rewarded by the interaction with a variety of patients.
My practice team includes Anna Morrison, R.N., Kerri Hugelmaier, N.P.
Conditions I Treat:
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Waldenstrom macroglobulinemia
- Chronic lymphocytic leukemia
Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Institute Director of Hematological Malignancies Clinical Research, and the Samuel Durand Professor of Medicine at the University of Rochester Medical Center. He is a driving force behind the operations of Wilmot’s clinical and research programs, leading a team of associate directors who help make decisions surrounding Wilmot’s clinical, research, education, and community outreach missions.
Dr. Friedberg serves as the editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO). He began this five-year term in June 2021. Prior to his editor-in-chief role, he served as associated editor of JCO. He has also served as a reviewer and on editorial boards for a number of medical journals.
Friedberg is a chair of the lymphoma committee in the SWOG group of the NCI National Clinical Trials Network and is an independently R01-funded investigator in the field of lymphoid malignancies.
Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.
His research interests focus on development of novel therapies for patients with lymphoma. He formerly received a Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma. He is currently funded as PI of the ILyAD trial, evaluating patients with follicular lymphoma receiving rituximab with a vitamin D intervention. As chair of SWOG, he is co-leader of the current North American intergroup effort in advanced stage Hodgkin lymphoma. He is also a founding member of the Lymphoma Epidemiology of Outcomes Consortium.
Faculty Academic Mentoring Award
Sponsor: University of Rochester School of Medicine and Dentistry
Location: University of Rochester
2008 - 2008
Scholar in Clinical Research
Sponsor: Leukemia and Lymphoma Society
2008 - 2008
America's Top Doctors Selection
2007 - 2007
Jacob Gitelman Award
Sponsor: Gilda's Club and Cancer Action
Location: Rochester, NY
2004 - 2006
Lawrence A. Kohn Senior Teaching Fellow
Sponsor: Institute of Medicine
Location: Outstanding Teaching Contributions, Department of Medicine, Univ
2003 - 2003
Clinical Investigator Career Development Award
Sponsor: Lymphoma Research Foundation
2001 - 2003
Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease"
Sponsor: Berlex Oncology Foundation
2001 - 2003
Rising stars program for innovative research
Sponsor: Dunkin Donuts and Dana-Farber Cancer Institute Department of Adu
VIEW ALL expand_more
Torka P, Pederson LD, Knopp MV, Poon D, Zhang J, Kahl BS, Higley HR, Kelloff G, Friedberg JW, Schwartz LH, Wilson WH, Leonard JP, Bartlett NL, Schöder H, Ruppert AS. "Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis." Cancer medicine. 2023 Feb 17; Epub 2023 Feb 17.
Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman J, Strouse CS, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS. "Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma." Blood.. 2023 Feb 3; Epub 2023 Feb 03.
Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM. "Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia." Blood advances.. 2023 Jan 23; Epub 2023 Jan 23.
Books & Chapters
Chapter Title: Beyond rituximab: the future of monoclonal antibody in B-cell non-Hodgkin's lymphoma.
Book Title: Current Oncology Reports
Author List: Sikder M, Friedberg JW:
Published By: Current Oncology Reports 2008
Chapter Title: : Non-Hodgkin's lymphomas
Book Title: Cancer, Principles & Practice of Oncology 8th edition
Author List: Friedberg JW, Mauch PM, Rimsza LM, Fisher RI
Published By: Lippincott Williams & Wilkins 2008
Chapter Title: Lymphocyte-predominant Hodgkin's lymphoma. Evidence-based Hematology
Book Title: Evidence-based Hematology
Author List: McMahon B, Friedberg JW
Published By: Evidence based Hematology 2008
VIEW ALL PUBLICATIONS